Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Revenue (2016 - 2026)

Sanofi's Revenue history spans 16 years, with the latest figure at $12.3 billion for Q1 2026.

  • On a quarterly basis, Revenue rose 18.21% to $12.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $51.4 billion, a 26.04% increase, with the full-year FY2025 number at $50.8 billion, up 15.68% from a year prior.
  • Revenue hit $12.3 billion in Q1 2026 for Sanofi, up from -$10.0 billion in the prior quarter.
  • Over the last five years, Revenue for SNY hit a ceiling of $46.3 billion in Q4 2023 and a floor of -$10.0 billion in Q4 2025.
  • Historically, Revenue has averaged $13.4 billion across 5 years, with a median of $10.9 billion in 2022.
  • Biggest five-year swings in Revenue: surged 323.51% in 2023 and later tumbled 245.37% in 2025.
  • Tracing SNY's Revenue over 5 years: stood at $10.9 billion in 2022, then surged by 323.51% to $46.3 billion in 2023, then crashed by 85.16% to $6.9 billion in 2024, then tumbled by 245.37% to -$10.0 billion in 2025, then surged by 223.1% to $12.3 billion in 2026.
  • Business Quant data shows Revenue for SNY at $12.3 billion in Q1 2026, -$10.0 billion in Q4 2025, and $37.8 billion in Q3 2025.